Incyte (INCY) Scheduled to Post Quarterly Earnings on Tuesday

Incyte (NASDAQ:INCY - Get Free Report) will be issuing its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.87 per share for the quarter. Investors interested in listening to the company's conference call can do so using this link.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.15 by ($0.09). The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Incyte had a return on equity of 12.56% and a net margin of 16.17%. The business's revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.44 EPS. On average, analysts expect Incyte to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Incyte Stock Down 0.5 %

Incyte stock traded down $0.27 during mid-day trading on Tuesday, reaching $51.65. The stock had a trading volume of 2,493,623 shares, compared to its average volume of 1,726,973. The company has a market capitalization of $11.60 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 1.21 and a beta of 0.65. The company has a 50-day moving average price of $57.18 and a two-hundred day moving average price of $57.82. Incyte has a one year low of $50.27 and a one year high of $75.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.55 and a quick ratio of 3.36.

Analyst Ratings Changes

A number of equities analysts recently issued reports on INCY shares. Cantor Fitzgerald assumed coverage on shares of Incyte in a research note on Tuesday. They issued a "neutral" rating on the stock. Stifel Nicolaus boosted their target price on Incyte from $67.00 to $68.00 and gave the stock a "hold" rating in a research report on Wednesday, February 14th. Jefferies Financial Group assumed coverage on Incyte in a research report on Friday, February 23rd. They issued a "buy" rating and a $81.00 target price for the company. Truist Financial decreased their target price on Incyte from $91.00 to $84.00 and set a "buy" rating for the company in a research report on Wednesday, February 14th. Finally, JMP Securities lowered Incyte from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 14th. Nine equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Incyte currently has an average rating of "Moderate Buy" and a consensus target price of $76.07.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.